Intradialytic Hypotension and Risk of Cardiovascular Disease

2014324 citationsJournal Articlebronze Open Access

Authors

Bergur V. Stefánsson · AstraZeneca (Sweden)

Steven M. Brunelli · DaVita Clinical Research (United States)

Claudia Cabrera · AstraZeneca (Sweden)

David P. Rosenbaum · Ardelyx (United States)

Emmanuel A. Anum · DaVita Clinical Research (United States)

Karthik Ramakrishnan · DaVita Clinical Research (United States)

Donna E. Jensen

Abstract

IDH was potently associated with cardiovascular morbidity and mortality. Clinical trials to ascertain causality are needed and should consider reduction in IDWG as a potential means to reduce IDH.

Topics & Keywords

Cardiovascular Health and Disease Prevention Hemodynamic Monitoring and Therapy Blood Pressure and Hypertension Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Journal of the American Society of Nephrology

Volume 9, Issue 12, pp. 2124-2132

DOI: 10.2215/cjn.02680314

Field-Weighted Citation Impact: 11.64